Cartesian Therapeutics, Inc. (NASDAQ:RNAC – Free Report) – HC Wainwright cut their Q3 2026 earnings per share estimates for shares of Cartesian Therapeutics in a report issued on Friday, August 7th. HC Wainwright analyst M. Kapoor now anticipates that the company will earn ($0.99) per share for the quarter, down from their prior forecast of ($0.94). HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Cartesian Therapeutics’ current full-year earnings is ($3.99) per share. HC Wainwright also issued estimates for Cartesian Therapeutics’ Q4 2026 earnings at ($1.06) EPS, FY2026 earnings at ($2.91) EPS, Q1 2027 earnings at ($1.09) EPS, Q2 2027 earnings at ($0.95) EPS, Q3 2027 earnings at ($0.82) EPS, Q4 2027 earnings at ($0.83) EPS and FY2027 earnings at ($3.62) EPS.
Other equities analysts have also recently issued research reports about the stock. Zacks Research raised shares of Cartesian Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 29th. Weiss Ratings upgraded shares of Cartesian Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, June 12th. Wedbush reissued an “outperform” rating and issued a $38.00 target price on shares of Cartesian Therapeutics in a research note on Wednesday, June 10th. Wall Street Zen raised Cartesian Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $40.00 price objective on shares of Cartesian Therapeutics in a report on Tuesday, June 9th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Cartesian Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $32.60.
Cartesian Therapeutics Price Performance
Shares of RNAC opened at $8.76 on Tuesday. Cartesian Therapeutics has a 1-year low of $5.60 and a 1-year high of $12.25. The company has a market capitalization of $264.99 million, a P/E ratio of -1.47 and a beta of 0.63. The firm’s 50 day simple moving average is $8.61 and its 200 day simple moving average is $7.56.
Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.88) by $1.34.
Hedge Funds Weigh In On Cartesian Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of the company. Bank of New York Mellon Corp bought a new stake in shares of Cartesian Therapeutics in the second quarter worth about $332,000. Renaissance Technologies LLC lifted its holdings in Cartesian Therapeutics by 63.7% in the 1st quarter. Renaissance Technologies LLC now owns 67,300 shares of the company’s stock worth $414,000 after buying an additional 26,200 shares during the period. Sei Investments Co. purchased a new stake in Cartesian Therapeutics in the 1st quarter worth approximately $78,000. Millennium Management LLC grew its position in shares of Cartesian Therapeutics by 548.2% in the 4th quarter. Millennium Management LLC now owns 164,366 shares of the company’s stock worth $1,185,000 after buying an additional 139,009 shares during the last quarter. Finally, 683 Capital Management LLC grew its position in shares of Cartesian Therapeutics by 21.7% in the 4th quarter. 683 Capital Management LLC now owns 280,000 shares of the company’s stock worth $2,019,000 after buying an additional 50,000 shares during the last quarter. 86.95% of the stock is owned by institutional investors.
Cartesian Therapeutics Company Profile
Cartesian Therapeutics, trading on NASDAQ under the symbol RNAC, is a clinical‐stage biotechnology company specializing in the development of messenger RNA (mRNA)-based therapeutics. The company leverages a proprietary RNA delivery platform to induce the production of therapeutic proteins within patients, aiming to address a range of diseases through in vivo expression of disease-modifying agents. Cartesian’s technology is designed to optimize mRNA stability, translation efficiency and targeted delivery, with potential applications spanning oncology, autoimmune disorders and rare genetic conditions.
At the core of Cartesian’s approach is a synthetic mRNA platform that incorporates proprietary lipid nanoparticle (LNP) formulations.
See Also
- Five stocks we like better than Cartesian Therapeutics
- China’s Athleisure Boom Is Not Lifting Every Brand Equally
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
Receive News & Ratings for Cartesian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cartesian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
